Unstable Plaques

Pathophysiological Background (brief)

Soft (lipid-rich, vulnerable) plaques in the coronary arteries have:

  • a thin fibrous cap
  • a high lipid and inflammatory content

 high risk of plaque rupture → thrombosis → myocardial infarction

Statins stabilize plaques not primarily through LDL lowering alone, but through:

  • reduction of the lipid core
  • anti-inflammatory effects (↓ CRP, ↓ macrophage activity)
  • thickening of the fibrous cap
  • endothelial stabilization

These effects are clearly dose dependent.

Guideline-Based Answer (ESC/EAS)

According to ESC/EAS guidelines, high-intensity statin therapy is required for plaque stabilization in coronary atherosclerosis.

High-intensity statin doses (plaque stabilization)

Statin

Dose

LDL reduction

Atorvastatin

40–80 mg/day

≥ 50%

Rosuvastatin

20–40 mg/day

≥ 50%

These doses are necessary to:

  • convert vulnerable plaques into more stable, fibrotic plaques
  • reduce the risk of acute coronary syndromes

Evidence from Imaging Studies

IVUS, OCT, and CT studies show:

  • Low doses: little to no effect on plaque morphology
  • High-intensity doses:
    • reduction of the necrotic lipid core
    • increase in fibrous cap thickness
    • partial plaque regression

Plaque stabilization is a high-dose effect.

Clinical Implication

If soft plaques are detected (e.g., by coronary CT angiography, IVUS):

  • the patient is functionally considered at very high cardiovascular risk
  • Targets:
    • LDL-C < 55 mg/dL
    • ≥ 50% LDL reduction
  • Approach:
    1. High-intensity statin (see above)
    2. If target not achieved → ezetimibe
    3. If needed → PCSK9 inhibitor

Important Clarification

Plaque stabilization at low statin doses is not supported by evidence.
Moderate doses lower LDL cholesterol but do not reliably stabilize vulnerable plaques.

How can I determine whether I have soft plaques in the coronary arteries?

Best Non-Invasive Method

Coronary CT Angiography (CCTA)

  • Can visualize non-calcified (soft) plaques
  • Allows plaque characterization, not just assessment of stenosis severity

Typical CT features of soft/vulnerable plaques:

  • Low attenuation (< 30–60 HU)
  • Positive remodeling
  • “Napkin-ring sign”
  • Spotty calcifications

Limitations:

  • No direct assessment of fibrous cap thickness
  • Radiation exposure (nowadays usually low)

Why Conventional Coronary Angiography Is Insufficient

Conventional coronary angiography is not suitable for reliably diagnosing soft plaques and can easily miss them.
Invasive coronary angiography visualizes only the vessel lumen, not the vessel wall or plaque composition.

Core problems:

  • Soft plaques often grow eccentrically
  • → so-called positive remodeling
  • → lumen remains normal in size for a long time
  • → angiographically “normal” appearance despite significant plaque burden

Result: highly vulnerable plaques may be angiographically invisible.

What Coronary Angiography Can Do

  • Excellent detection of high-grade luminal stenoses
  • Essential for planning interventions
  • Acute diagnostics in STEMI/NSTEMI

What It Cannot Do

  • No differentiation between:
    • soft plaques
    • fibrous plaques
    • calcified plaques
  • No assessment of fibrous cap thickness
  • No evaluation of plaque vulnerability

Clinically Particularly Important

  • Acute coronary syndromes often arise from:
    • non–high-grade stenotic
    • but vulnerable soft plaques
  • Many “culprit lesions” were previously < 50% stenosis on angiography

Key Message

Stabilization of soft coronary plaques requires high-intensity statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg).
The effect is dose dependent and an integral component of myocardial infarction prevention.

“Plaque stabilization by high-intensity statins (atorvastatin 40–80 mg / rosuvastatin 20–40 mg), dose/exposure dependence, and evidence from imaging and outcome studies”:

References

  1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455.
  2. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: the REVERSAL trial. JAMA. 2004;291(9):1071–1080.
  3. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high–intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–1565.
  4. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary atherosclerosis (SATURN). N Engl J Med. 2011;365:2078–2087. doi:10.1056/NEJMoa1110874.
  5. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes (MIRACL). JAMA. 2001;285(13):1711–1718. doi:10.1001/jama.285.13.1711.
  6. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE IT–TIMI 22). N Engl J Med. 2004;350:1495–1504. doi:10.1056/NEJMoa040583.
  7. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease (TNT). N Engl J Med. 2005;352:1425–1435. doi:10.1056/NEJMoa050461.
  8. Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque assessed by OCT (EASY-FIT). J Am Coll Cardiol. 2014. (Atorvastatin 20 mg vs 5 mg; dose-dependent increase in cap thickness).
  9. Ozaki Y, et al. Effect of statin therapy on fibrous cap thickness in coronary plaque on optical coherence tomography: review and meta-analysis. 2019.